MedTrace Logo

Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours

NCT00189410 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2010-07-20

No results posted yet for this study

Summary

Pegylated Liposomal Doxorubicin as well as Carboplatin have been showed efficacy in monotherapy as in combination therapy of gynaecologic tumours. As there is no common standard in the therapy of recurrent ovarian carcinoma, tumours of the uterus nor for non-epithelial ovarian tumours at time of designing of this study, this trial shall evaluate the new and well tolerated combination therapy consisting of Pegylated Liposomal Doxorubicin and Carboplatin.

Conditions

  • Cancer of the Ovary Treated as 2nd Line Therapy
  • Muellerian Mixed Tumours
  • Tumours of the Uterus
  • Cervical Cancers
  • Non-Epithelial Ovarian Tumours

Interventions

DRUG

Pegylated Liposomal Doxorubicin and Carboplatin

Sponsors & Collaborators

  • MedServ. GmbH, Wiesbaden

    collaborator UNKNOWN

  • Essex Pharma GmbH

    collaborator INDUSTRY

  • AGO Study Group

    lead OTHER

Principal Investigators

  • Andreas du Bois, MD PhD · AGO-OVAR, AGO Ovarian Cancer Study Group

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2005-09-30
Completion
2006-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00189410 on ClinicalTrials.gov